Supriya Lifescience

    SUPRIYA
    Pharma
    ₹614.80
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹4,948 Cr

    P/E
    27.93
    Day range
    ₹610.80 – ₹620.95
    52-week range
    ₹545.50 – ₹1,085.00
    Volume
    1.93 L
    Open
    ₹616.20
    Prev close
    ₹620.65

    Latest results · Q2 FY27(standalone)Revenue ₹206 Cr+3.2%Profit ₹29 Cr-42.0%Margin 14.2%YoY vs the same quarter last year

    1 red flag to read up on

    • high

      Under Additional surveillance (ASM)

      The exchange has put this stock under Additional surveillance (ASM), Stage I · 18 Nov 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 50 / 100

    Factor percentiles

    Value50
    Quality76
    Momentum30
    Low volatility43

    Derived metrics

    Earn. yield
    3.6%
    12-1 mom.
    +17.2%
    Return / vol
    -0.37
    Magic Formula
    #129
    FCF yield
    0.7%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Supriya LifescienceSUPRIYA₹4,948 Cr27.93—19.0%25.0%22.0%0.00+3.0%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 21h ago

    Headlines about Supriya Lifescience from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    ROE (FY26)
    19.0%
    ROCE (latest year)
    25%

    Moving averages (NSE)

    20-day
    ₹762.88
    Price below
    50-day
    ₹851.81
    Price below
    200-day
    ₹783.71
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +21.6%
    Profit 3Y CAGR
    +32.4%
    Revenue YoY (Sep 2026 (S))
    +3.0%
    Profit YoY (Sep 2026 (S))
    -42.0%
    Operating margin
    22.0%
    Net margin
    14.1%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr100 Cr200 Cr300 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023 (S)Jun 2024 (S)Dec 2024 (S)Jun 2025 (S)Dec 2025 (S)Sep 2026 (S)0%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2018 (S)Mar 2020 (S)Mar 2022 (S)Mar 2024 (S)Mar 2026 (S)-200 Cr-100 Cr0 Cr100 Cr200 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY18FY19FY20FY21FY22FY23FY24FY25FY260%20%40%60%80%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr500 Cr1K Cr1.5K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2019 (S)Mar 2021 (S)Mar 2023 (S)Mar 2025 (S)Sep 2026 (S)0x2x4x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023 (S)Mar 2024 (S)Jun 2024 (S)Sep 2024 (S)Dec 2024 (S)Mar 2025 (S)Jun 2025 (S)Sep 2025 (S)Dec 2025 (S)Mar 2026 (S)Jun 2026 (S)Sep 2026 (S)
    Sales140158161166186184145200206277190206
    YoY Sales growth——————-10—————
    Expenses991039810112011793127134179142161
    Operating Profit415663656668527372984745
    OPM %30%35%39%39%36%37%36%36%35%35%25%22%
    Other Income322323332332
    Interest010010100000
    Depreciation445556677899
    Profit before tax405360626364476867924138
    Tax %26%31%25%26%25%21%27%26%26%19%41%23%
    Net Profit303745464750355050742429
    EPS in Rs₹3.70₹4.59₹5.55₹5.73₹5.81₹6.26₹4.32₹6.27₹6.17₹9.22₹2.99₹3.63

    From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days97

    +28 days since Mar 2021 (S)

    Inventory Days229

    +23 days since Mar 2021 (S)

    Days Payable159

    +14 days since Mar 2021 (S)

    Cash Conversion Cycle167

    +37 days since Mar 2021 (S)

    Working Capital Days147

    +119 days since Mar 2021 (S)

    Strengths, risks & growth

    Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. [1]

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter68.30%68.30%68.30%68.30%0.00 pp
    FII5.19%5.16%6.18%6.45%+0.27 pp
    DII5.00%5.70%5.30%5.47%+0.17 pp
    Public21.49%20.83%20.21%19.80%-0.41 pp

    Filed with NSE for Sept 2026: promoters 68.30%, public 31.70%

    Analysts & fund holdings

    100%
    100% recommend buy
    1 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E27.9 vs 45.1
    Sector P/B6.03
    Beta0.58

    Who holds the shares, quarter by quarter

    Mutual funds 1.28% (-0.01 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters68.3%
    • Foreign institutions6.4%
    • Mutual funds1.3%
    • Insurance2.4%
    • Other domestic institutions1.8%
    • Retail14.2%
    • Others5.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Abakkus Flexi Cap Fund0.88%0.56%-0.18 pp
    ITI Large & Mid Cap Fund0.21%1.49%-0.01 pp
    Quantum Small Cap Fund0.18%3.75%+0.12 pp
    ITI ELSS Tax Saver Fund0.15%1.87%+0.13 pp
    Motilal Oswal Nifty Microcap 250 Index Fund0.12%0.27%+0.02 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Avg

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    51.1%
    Downside volatility
    53.8%
    Worst 5% of days
    4.2%
    Average of that tail
    8.1%
    Max drawdown (1Y)
    41.6%
    Below its peak
    41.6%

    Against the market

    Beta vs Nifty 50
    0.49
    Correlation
    0.13
    Relative strength (3M)
    -25.5%
    ATR (14)
    5.9%

    Return

    Return 1M
    -30.6%
    Return 3M
    -21.6%
    Return 6M
    -10.1%
    Return 1Y
    -18.7%
    vs 200-day average
    -21.6%

    Momentum

    RSI (14) · oversold
    23.3
    MACD histogram
    -18.09
    Stochastic %K
    5.9
    ADX (14)
    33.8
    +DI / −DI
    11.3 / 46.0
    Money flow index
    15.2

    Participation

    Delivery (20d avg)
    44.3%
    vs its 60-day baseline
    +1.1 pts
    Volume vs 20-day
    -0.3σ
    Close vs day's VWAP
    -0.0%
    52-week position
    12 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    No F-Score: it needs two reporting periods a year apart that carry both an income statement and a balance sheet, and this company's filings do not yet line up that way. The ratios below need only the one period and are unaffected.

    Free cash flow
    ₹34 Cr
    FCF yield
    0.7%
    Net debt
    -₹35 Cr
    Net debt / equity
    -0.03
    EV / sales
    5.64

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      4 Sept 2026
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      4 Sept 2025
      ex-date
    • dividend
      ₹0.80

      Annual General Meeting/Dividend - Rs 0.80 Per Share

      20 Sept 2024
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 0.60 Per Share

      15 Sept 2023
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 0.60 Per Share

      1 Sept 2022
      ex-date

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 6 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Supriya Lifescience: common questions

    Answered from the figures on this page.

    Supriya Lifescience last traded at ₹614.80 (NSE, as of 18 Nov 2026). The last session moved it down 0.94%.

    Supriya Lifescience is valued at about ₹4,948 crore (NSE, as of 18 Nov 2026).

    Supriya Lifescience trades at a price-to-earnings ratio of 27.93 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Supriya Lifescience has traded between ₹545.50 and ₹1,085.00 over the past 52 weeks, to 18 Nov 2026. It is currently 13% of the way up that range.

    Supriya Lifescience (SUPRIYA) is classified under Pharma on this site's screener.